A US Shortage of Estradiol Patches Is Squeezing Menopause and Gender-Affirming Care

A nationwide shortage of estradiol patches is making prescriptions difficult to fill across the United States, with availability varying by pharmacy and region. The FDA says it is working with six drug-device manufacturers to expand supply.

A shortage caused by demand, not failure

Most drug shortages follow a manufacturing problem — a contaminated line, a failed inspection, a plant closure. This one is different: it is being driven by a surge in demand, which makes it both more encouraging and harder to fix quickly.

Two populations are competing for the same supply. More perimenopausal and postmenopausal people are using hormone replacement therapy for hot flashes, night sweats and bone loss. And transgender and non-binary people use estradiol for gender-affirming care. Both groups depend on consistent access to a specific formulation.

The twenty-year context behind the surge

Understanding why demand rose so sharply requires going back to 2002, when the Women’s Health Initiative halted a major arm of its hormone therapy trial early over safety findings. Prescribing collapsed almost overnight, and a boxed warning — the FDA’s strongest labelling designation — was applied to hormone therapy products.

Subsequent reanalysis substantially complicated that picture. Risk was found to depend heavily on age at initiation, time since menopause, and the specific formulation and route — distinctions the original blanket warning did not capture. A generation of clinicians nevertheless trained under the assumption that hormone therapy was dangerous, and many patients went untreated for symptoms that materially affected their lives.

In November 2025, the FDA removed the long-standing boxed warning from some HRT products. Demand rose further, and the current shortage is in part the consequence of correcting a two-decade distortion faster than manufacturing could follow.

Why patches specifically

Patches are not interchangeable with tablets, for a reason rooted in physiology. Oral estradiol passes through the liver before reaching general circulation — first-pass metabolism — which alters production of clotting factors. Transdermal delivery bypasses the liver, and is associated with a lower risk of venous thromboembolism than oral administration.

For many patients, particularly those with cardiovascular or clotting risk factors, the patch is not a preference but a clinical choice. That is why a shortage of one formulation cannot simply be absorbed by another.

Why patches are hard to scale

The FDA’s reference to drug-device manufacturers is the key detail. A transdermal patch is a combination product, not a pill — it is a layered adhesive matrix engineered to release drug at a controlled rate across days, and it is regulated accordingly.

Scaling that up is slower than scaling tablet production. The adhesive chemistry must deliver consistent flux, the laminate is produced on specialised coating equipment, and any change to materials or process can alter release kinetics enough to require new data. Capacity cannot be improvised.

What the FDA is doing

The agency says it is fast-tracking regulatory submissions from the six manufacturers and urging them to increase output through additional production shifts, larger batch sizes and specialised equipment.

That is a realistic list, and a limited one. Extra shifts and larger batches use existing lines harder; new equipment takes time to install and qualify. Notably, no figures were provided on the shortage’s size or when it is expected to ease — which usually means the answer is not yet known.

What patients can do

Alternatives exist — gels, sprays, tablets, different patch strengths and brands — but switching is not trivial. Different routes have different absorption profiles, dose equivalence is approximate, and re-stabilising can take weeks. For someone whose therapy is carefully titrated, an involuntary switch is a genuine disruption rather than an inconvenience.

The practical advice is to speak with a prescriber or pharmacist about options rather than stopping therapy independently. Abrupt discontinuation of estradiol can cause a rapid return of symptoms, and for people on gender-affirming therapy the consequences of an unplanned interruption extend well beyond discomfort.

The structural point

How shortages usually resolve, and why this one may be slower

Supply disruptions caused by a manufacturing failure follow a familiar arc: the problem is fixed, the line restarts, and existing capacity refills the pipeline. Demand-driven shortages behave differently, because the capacity itself is the constraint rather than its temporary loss.

Expanding output means either running current lines harder — which extra shifts and larger batches achieve, but only up to a ceiling — or installing new capacity, which for a combination product involves equipment procurement, installation, qualification and regulatory notification. That sequence is measured in quarters, not weeks.

There is also a forecasting problem. Manufacturers plan capacity years ahead against projected demand, and nobody modelled a step change in hormone therapy prescribing driven by a labelling decision. Until demand stabilises at a new level, companies face a genuine commercial question about how much permanent capacity to build for it.

It is worth noting what this shortage reveals. A supply base sized to two decades of artificially suppressed demand could not absorb a correction, and the product involved is one where substitution is medically constrained and manufacturing is slow to expand. Regulatory decisions that change prescribing behaviour have supply consequences, and those consequences arrive faster than capacity can. Informational only; not medical advice.